Regenicin, Inc. (RGIN)

Market Cap	153.00 -99.0%
Revenue (ttm)	n/a
Net Income	-985.39K
EPS	-0.01
Shares Out	153.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,000
Open	0.000001
Previous Close	n/a
Day's Range	0.000001 - 0.000001
52-Week Range	0.000001 - 0.7501
Beta	37.12
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Regenicin

Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: RGIN

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 30, 2026

Data Sources Report a data error